Lv5
830 积分 2025-08-21 加入
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
6天前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
10天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
10天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
12天前
已完结
Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01
13天前
已完结
Impact of trop-2 expression on the efficacy of trop-2–targeted antibody–drug conjugates in metastatic breast cancer: a systematic review and meta-analysis
13天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
13天前
已完结
Emerging importance of HER3 in tumorigenesis and cancer therapy
18天前
已完结
Is There Still Room for Monotherapy in EGFR-Mutated Non-Small Cell Lung Cancer?
18天前
已完结
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
27天前
已完结
皖公网安备34019202002308
